Section Arrow
VCEL.NASDAQ
- Vericel Corp
Quotes are at least 15-min delayed:2025/11/22 16:04 EST
Regular Hours
Last
 39.58
+1.73 (+4.57%)
Day High 
40.1057 
Prev. Close
37.85 
1-M High
43 
Volume 
702.01K 
Bid
39.19
Ask
42.23
Day Low
37.82 
Open
37.91 
1-M Low
33.7637 
Market Cap 
1.91B 
Currency 美元 
P/E 145.58 
%Yield -- 
10-SMA 39.44 
20-SMA 37.87 
50-SMA 34.83 
52-W High 63 
52-W Low 29.24 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.26/0.74
Enterprise Value
2.00B
Balance Sheet
Book Value Per Share
6.36
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
237.22M
Operating Revenue Per Share
3.66
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OSRHOSR Holdings Inc.0.5626+0.1066+23.38%-- 
SGMOSangamo Therapeutics0.4234+0.0384+9.97%-- 
RXRXRecursion Pharmaceuticals4.17+0.32+8.31%-- 
CYPHCypherpunk Technologies Inc.2.28-0.66-22.45%-- 
ASBPAspire Biopharma Holdings Inc.0.0974-0.0003-0.31%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.